Researchers have made a groundbreaking discovery in the field of hematology, providing an explanation for spontaneous and unusual blood-clotting that continues to occur despite treatment with ...
Four years after receiving Hemgenix in a Phase 3 trial, bleeding rates and the use of replacement therapy are low for men with hemophilia B.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback